Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive entities : Merck & company, inc. save search
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Published: 2024-03-19 (Crawled : 13:30) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: 0.0%
H: 0.68%
C: 0.63%
pneumococcal vaccine merck positive
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Published: 2023-11-10 (Crawled : 14:00) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: 0.45%
H: 0.51%
C: -1.41%
keytruda chmp merck positive cancer treatment plus gemcitabine
Merck Receives Positive EU CHMP Opinion for PREVYMIS® for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease
Published: 2023-10-17 (Crawled : 12:00) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: -0.13%
H: 0.47%
C: 0.16%
prevymis disease chmp kidney merck positive infection risk
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction
Published: 2023-07-21 (Crawled : 13:20) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: 0.25%
H: 1.73%
C: 1.53%
keytruda chmp merck positive treatment plus
Merck Receives Positive European Union CHMP Opinion for Gefapixant
Published: 2023-07-21 (Crawled : 13:20) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: 0.25%
H: 1.73%
C: 1.53%
chmp merck positive
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Published: 2023-06-16 (Crawled : 12:00) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: 0.09%
H: 0.87%
C: -0.16%
keytruda treatment plus
Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)
Published: 2022-10-10 (Crawled : 11:00) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: 2.66%
H: 1.84%
C: 0.61%
treatment hypertension trial positive
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
Published: 2022-09-22 (Crawled : 11:00) - biospace.com/
FNCTF | News | $11.0354 320
|
Communications
|
| O: 5.36%
H: 0.0%
C: -1.08%
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: 0.02%
H: 4.26%
C: 3.5%
lynparza treatment approved china cancer ovarian cancer
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children
Published: 2022-09-16 (Crawled : 12:00) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: -0.17%
H: 1.47%
C: 1.29%
chmp children positive vaccine pneumococcal
LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
Published: 2022-06-27 (Crawled : 11:00) - biospace.com/
FNCTF | News | $11.0354 320
|
Communications
|
| O: 0.62%
H: 0.0%
C: -0.35%
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: -0.16%
H: 2.7%
C: 1.3%
lynparza treatment chmp positive cancer her2- her2
Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
Published: 2022-06-21 (Crawled : 11:00) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
vaccine positive phase 1 pneumococcal
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery
Published: 2021-12-17 (Crawled : 14:00) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: 1.46%
H: 0.0%
C: 0.0%
keytruda renal cel positive therapy chmp cell carcinoma
Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection
Published: 2021-10-25 (Crawled : 12:00) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: -0.1%
H: 0.86%
C: 0.78%
treatment positive results trials phase 3 trial hiv topline injection infections
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older
Published: 2021-10-15 (Crawled : 14:00) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: -0.17%
H: 1.1%
C: 0.17%
positive chmp vaccine order pneumococcal
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50% Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
Published: 2021-10-01 (Crawled : 11:00) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: 8.59%
H: 3.41%
C: -0.2%
covid risk positive antiviral phase 3 molnupiravir
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)
Published: 2021-09-17 (Crawled : 13:00) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
positive therapy cancer breast cancer chmp keytruda
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
Published: 2021-05-24 (Crawled : 12:00) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: 0.44%
H: 0.15%
C: -0.63%
treatment positive therapy cancer chmp her2+ keytruda her2- her2
Merck Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine
Published: 2021-05-20 (Crawled : 11:00) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: -4.02%
H: 1.34%
C: 0.92%
positive results topline vaccine phase 3 pneumococcal
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
Published: 2021-05-05 (Crawled : 01:00) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: 0.14%
H: 2.14%
C: 2.1%
treatment fda positive therapy fda approval her2+ keytruda her2- her2
Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA® (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Published: 2021-02-01 (Crawled : 15:00) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: 1.19%
H: 0.44%
C: -0.81%
positive approval chmp keytruda
Gainers vs Losers
| 70% | 30% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.